IOIsabela Penteriche de Oliveira

Isabela Penteriche de Oliveira

*This is an algorithmically generated author record based on publicly available information.

Isabela Penteriche de Oliveira has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines

    by Amanda Izeli Portilho, Valéria Oliveira Silva, Hernan Hermes Monteiro Da Costa, Rosemeire Yamashiro, Isabela Penteriche de Oliveira, Ivana Barros de Campos, Carlos Roberto Prudencio, Elaine Monteiro Matsuda, Luís Fernando de Macedo Brígido, Elizabeth De Gaspari

    Humoral response to SARS-CoV-2 has been studied, predominantly the classical IgG and its subclasses. Although IgE antibodies are typically specific to allergens or parasites, a few reports describe their production in response to SARS-CoV-2 and other viruses. Here, we investigated IgE specific to receptor binding domain (RBD) of SARS-CoV-2 in a Brazilian cohort following natural infection and vaccination. Samples from 59 volunteers were assessed after infection (COVID-19), primary immunization with vectored (ChAdOx1) or inactivated (CoronaVac) vaccines, and booster immunization with mRNA (BNT162b2) vaccine. Natural COVID-19 induced IgE, but vaccination increased its levels. Subjects vaccinated with two doses of ChAdOx1 exhibited a more robust response than those immunized with two doses of CoronaVac; however, after boosting with BNT162b2, all groups presented similar IgE levels. IgE showed intermediate-to-high avidity, especially after the booster vaccine. We also found IgG4 antibodies, mainly after the booster, and they moderately correlated with IgE. ELISA results were confirmed by control assays, using IgG depletion by protein G and lack of reactivity with heterologous antigen. In our cohort, no clinical data could be associated with the IgE response. We advocate for further research on IgE and its role in viral immunity, extending beyond allergies and parasitic infections.


  • Open Access

    Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction

    by Elaine Monteiro Matsuda, Ivana Barros Campos, Isabela Penteriche de Oliveira, Daniela Rodrigues Colpas, Giselle Ibete Silva López-Lopes, Victor Oliveira Chiavegato, Luís Fernando de Macedo Brígido


  • Open Access

    Impact of covid-19 on people living with HIV-1: care and prevention indicators at a local and nationwide level, Santo André, Brazil

    by Elaine Monteiro Matsuda, Isabela Penteriche de Oliveira, Laura Ballesteros Bao, Fernanda Matsuda Manzoni, Norberto Camilo Campos, Beatriz Brajal Varejão, Maristelly Pereira Leal, Vania Barbosa Nascimento, Luís Fernando de Macedo Brígido

    The world has been dealing with Aids for forty years, covid-19 accentuated societal inequalities and promoted a rupture in care and prevention, including for people living with HIV. We compiled official HIV indicators, analyzed the impact of covid-19 in Brazil, at São Paulo State (SP), and compared it to the municipality of Santo André (in the state of São Paulo), which adopted linkage/retention strategies to mitigate the impact of covid-19. From 2019 to 2020, suppression/adhesion rates remained stable. The number of new treatments decreased both in Brazil (-19.75%) and São Paulo (-16.44%), but not in Santo André, where 80% of new patients started treatment within 30 days from their first TCD4 test (70% in São Paulo and 64% in Brazil). However, PrEP dispensing increased during this period. The distribution of 2,820 HIV self-tests in Santo André lead to only one documented new HIV diagnosis linked to care. Synergistic strategies to swiftly diagnose and connect new cases, ensuring retention as well as rescuing missing patients deserve priority in the fight against HIV, especially in times of covid-19.


  • Open Access

    Inhibition of receptor‐binding domain—ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS‐CoV‐2 vaccines

    by Valéria Oliveira Silva, Rosemeire Yamashiro, Cintia Mayumi Ahagon, Ivana Barros de Campos, Isabela Penteriche de Oliveira, Elaine Lopes de Oliveira, Giselle I. S. López‐Lopes, Elaine Monteiro Matsuda, Marcia Jorge Castejon, Luís Fernando de Macedo Brígido

    Practical laboratory proxies that correlate to vaccine efficacy may facilitate trials, identify nonresponders, and inform about boosting strategies. Among clinical and laboratory markers, assays that evaluate antibodies that inhibit receptor‐binding domain (RBD) ligation to angiotensin‐converting enzyme‐2 receptor (receptor‐binding inhibition [RBI]) may provide a surrogate for viral neutralization assays. We evaluated RBI before and after a median of 34 days (interquartile range [IQR]: 33–40) of the second dose of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Sinovac's CoronaVac (CN) or AstraZeneca/Oxford's AZD1222 (AZ) vaccines in 166 individuals. Both vaccines elicited high inhibitory titers in most subjects, 95% (158/166), with signal inhibition above 30% and 89% (127/143) with more than fourfold increase from prevaccination titers, but titers tend to decrease over time. Both postvaccination inhibitory titers (95%, IQR 85%–97% for AZ vs. 79%, IQR 60%–96% for CN, p = 0.004) and pre/post‐titer increase (AZ 76%, IQR 51%–86% for AZ vs. 47%, IQR 24%–67% for CN, p < 0.0001) were higher among AZ vaccinees. Previous serological reactivity due to natural infection was associated with high prevaccination signal inhibition titers. The study documents a robust antibody response capable of interfering with RBD–angiotensin‐converting enzyme binding. Evaluation of SARS‐CoV‐2 infection incidence in these populations is necessary to assess its association to protection and its duration.


  • A simple algorithm for selecting cases to investigate acute and early HIV infections in low‐ and middle‐income countries

    by Elaine Monteiro Matsuda, Cintia Mayumi Ahagon, Luana Portes Ozório Coelho, Ivana Barros Campos, Daniela Rodrigues Colpas³, Norberto Camilo Campos², Giselle Ibete Silva López‐Lopes, Valeria Oliveira Silva, Isabela Penteriche de Oliveira, Luís Fernando de Macedo Brígido

    We documented the outcome of an over 10-year (2011-2021) effort to diagnose acute and early HIV infections (AEHI) in an Infectious Diseases Outpatient Clinic with limited resources. Of a total of 132, 119 HIV-RNA tests were performed from 2017-2020, 12 cases were identified, using a simple algorithm: risk exposure of six weeks or less before the visit and/or symptoms compatible with acute retroviral syndrome 7-30 days after exposure and/or undetermined 3rd generation rapid diagnostic test or serology. AEHI diagnoses varied from 2.4% among asymptomatic to 25% for undetermined serology cases using this simple screening applicable to different settings.


  • Open Access

    Field evaluation of COVID‐19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by immediate results, technical simplicity, and low cost

    by Elaine Monteiro Matsuda, Ivana Barros de Campos, Isabela Penteriche de Oliveira, Daniela Rodrigues Colpas, Andreia Moreira dos Santos Carmo, Luís Fernando de Macedo Brígido

    One year into the COVID‐19 pandemic, diagnostic strategies, although central for contact tracing and other preventive measures, are still limited. To meet the global demand, lower cost and faster antigen tests for SARS‐CoV‐2 detection are a convenient alternative to the gold standard RT‐PCR assay. We tested laboratory‐based RT‐PCR RNA detection and two rapid antigen detection (RAD) tests, based on the immunochromatography test for nucleocapsid protein of SARS‐CoV‐2 (COVID‐19 Ag ECO Test, ECO Diagnóstica, Brazil, and PanbioTM COVID‐19 Ag Rapid Test Abbott, Germany). Paired collection and testing were done in a small prospective open study in three clinical services in São Paulo, constituted of mostly symptomatic volunteers at collection (97%, 109/112) for a median of 4 days (IQR 3‐6), ranging from 1 to 30. Among the 108 paired RT‐PCR/RAD tests, results were concordant in 96.4% (101/108). The test's performance was comparable, with an overall sensitivity of 87% and a specificity of 96%. These observations add to other data that suggest that antigen tests may provide reasonable sensitivity and specificity and deserve a role to improve testing strategies, especially in resource‐limited settings.